We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+6.18%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$17.6B
AUM Growth
+$224M
Cap. Flow
-$30.2M
Cap. Flow %
-0.17%
Top 10 Hldgs %
87.48%
Holding
123
New
5
Increased
24
Reduced
7
Closed
6

Top Buys

Rank Stock Value
1
REPL icon
Replimune Group
REPL
+$32.5M
2
ASND icon
Ascendis Pharma A/S
ASND
+$29.3M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$23.6M
4
CCXI
ChemoCentryx, Inc.
CCXI
+$19.3M
5
NRIX icon
Nurix Therapeutics
NRIX
+$16.2M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$63.5M
2
LEGN icon
Legend Biotech
LEGN
+$48.7M
3
AXSM icon
Axsome Therapeutics
AXSM
+$25.3M
4
MRUS
Merus
MRUS
+$21.8M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$9.64M

Sector Composition

Rank Sector Weight
1 Healthcare 99.55%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SGEN
1
DELISTED
Seagen Inc. Common Stock
SGEN
$8.3B 47.09%
46,912,266
– –
INCY icon
2
Incyte
INCY
$25.9B
$2.75B 15.58%
36,154,117
+433
+0% +$32.9K
ONC
3
BeOne Medicines Ltd
ONC
$42.4B
$1.89B 10.71%
11,668,897
– –
BMRN icon
4
BioMarin Pharmaceuticals
BMRN
$12.9B
$632M 3.58%
7,620,494
– –
ACAD icon
5
Acadia Pharmaceuticals
ACAD
$5.08B
$591M 3.35%
41,923,486
+12,782
+0% +$239K
ASND icon
6
Ascendis Pharma A/S
ASND
$16.6B
$451M 2.56%
4,852,655
+311,051
+7% +$29.3M
ARGX icon
7
argenx
ARGX
$65B
$424M 2.41%
1,119,557
– –
BCRX icon
8
BioCryst Pharmaceuticals
BCRX
$2.44B
$134M 0.76%
12,710,818
– –
KOD icon
9
Kodiak Sciences
KOD
$2.41B
$132M 0.75%
17,310,490
+1,379,445
+9% +$9.69M
GBT
10
DELISTED
Global Blood Therapeutics, Inc.
GBT
$119M 0.68%
3,732,502
+417,737
+13% +$12.2M
ABCL icon
11
AbCellera Biologics
ABCL
$3.67B
$111M 0.63%
10,450,180
– –
MDGL icon
12
Madrigal Pharmaceuticals
MDGL
$11.9B
$107M 0.61%
1,499,213
– –
MRTX
13
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$94.6M 0.54%
1,409,784
– –
IMCR icon
14
Immunocore
IMCR
$1.9B
$94M 0.53%
2,520,730
– –
HZNP
15
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$91.6M 0.52%
1,148,504
+249,662
+28% +$23.6M
CERS icon
16
Cerus
CERS
$566M
$85M 0.48%
16,067,558
+2,354,363
+17% +$11.8M
TVTX icon
17
Travere Therapeutics
TVTX
$6.19B
$80M 0.45%
3,300,009
– –
REPL icon
18
Replimune Group
REPL
$1.39B
$62.8M 0.36%
3,591,081
+1,979,378
+123% +$32.5M
TRDA icon
19
Entrada Therapeutics
TRDA
$295M
$59.3M 0.34%
4,865,819
+161,400
+3% +$1.22M
IGMS
20
DELISTED
IGM Biosciences
IGMS
$56.9M 0.32%
3,156,102
– –
KYMR icon
21
Kymera Therapeutics
KYMR
$9.96B
$56.7M 0.32%
2,879,825
+495,083
+21% +$11.6M
KRYS icon
22
Krystal Biotech
KRYS
$10.3B
$53M 0.3%
807,735
– –
PRLD icon
23
Prelude Therapeutics
PRLD
$529M
$52.8M 0.3%
10,123,824
– –
NRIX icon
24
Nurix Therapeutics
NRIX
$2.77B
$49.2M 0.28%
3,882,125
+1,428,043
+58% +$16.2M
LEGN icon
25
Legend Biotech
LEGN
$4.24B
$47.1M 0.27%
856,658
-1,152,341
-57% -$48.7M
1
2 3 4 5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q2 2022 Portfolio in Review

As of Q2 2022, Julian Baker held 123 positions worth $17.6B, up 1.3% from $17.4B the previous quarter. Its ten largest holdings account for 87% of the portfolio.

Julian Baker's Q2 2022 filing shows 5 new, 24 increased, 7 reduced and 6 closed positions. Its largest new stake was Vor Biopharma: 56,938 shares worth $5.66M. The largest sale was Neurocrine Biosciences, an estimated $63.5M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.

  • Julian Baker's largest Q2 2022 buy was Vor Biopharma: 56,938 shares worth $5.66M.
  • Julian Baker added most to Replimune Group in Q2 2022, an estimated $32.5M increase.
  • Julian Baker's biggest Q2 2022 reduction was Legend Biotech, cutting an estimated $48.7M.
  • Julian Baker fully exited Neurocrine Biosciences in Q2 2022, selling an estimated $63.5M.
  • Julian Baker's ten largest holdings make up 87% of its $17.6B portfolio in Q2 2022.
  • Julian Baker opened 5 new positions and closed 6 in Q2 2022.
  • Julian Baker's portfolio value rose 1.3% quarter-over-quarter to $17.6B.

Based on Baker Bros. Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.